Literature DB >> 28399252

Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition.

Rebecca F Gottesman1, Andrea L C Schneider2, Yun Zhou3, Josef Coresh4, Edward Green5, Naresh Gupta6, David S Knopman7, Akiva Mintz8, Arman Rahmim3, A Richey Sharrett4, Lynne E Wagenknecht9, Dean F Wong10, Thomas H Mosley11.   

Abstract

IMPORTANCE: Midlife vascular risk factors have been associated with late-life dementia. Whether these risk factors directly contribute to brain amyloid deposition is less well understood.
OBJECTIVE: To determine if midlife vascular risk factors are associated with late-life brain amyloid deposition, measured using florbetapir positron emission tomography (PET). DESIGN, SETTING, AND PARTICIPANTS: The Atherosclerosis Risk in Communities (ARIC)-PET Amyloid Imaging Study, a prospective cohort study among 346 participants without dementia in 3 US communities (Washington County, Maryland; Forsyth County, North Carolina; and Jackson, Mississippi) who have been evaluated for vascular risk factors and markers since 1987-1989 with florbetapir PET scans in 2011-2013. Positron emission tomography image analysis was completed in 2015. EXPOSURES: Vascular risk factors at ARIC baseline (age 45-64 years; risk factors included body mass index ≥30, current smoking, hypertension, diabetes, and total cholesterol ≥200 mg/dL) were evaluated in multivariable models including age, sex, race, APOE genotype, and educational level. MAIN OUTCOMES AND MEASURES: Standardized uptake value ratios (SUVRs) were calculated from PET scans and a mean global cortical SUVR was calculated. Elevated florbetapir (defined as a SUVR >1.2) was the dependent variable.
RESULTS: Among 322 participants without dementia and with nonmissing midlife vascular risk factors at baseline (mean age, 52 years; 58% female; 43% black), the SUVR (elevated in 164 [50.9%] participants) was measured more than 20 years later (median follow-up, 23.5 years; interquartile range, 23.0-24.3 years) when participants were between 67 and 88 (mean, 76) years old. Elevated body mass index in midlife was associated with elevated SUVR (odds ratio [OR], 2.06; 95% CI, 1.16-3.65). At baseline, 65 participants had no vascular risk factors, 123 had 1, and 134 had 2 or more; a higher number of midlife risk factors was associated with elevated amyloid SUVR at follow-up (30.8% [n = 20], 50.4% [n = 62], and 61.2% [n = 82], respectively). In adjusted models, compared with 0 midlife vascular risk factors, the OR for elevated SUVR associated with 1 vascular risk factor was 1.88 (95% CI, 0.95-3.72) and for 2 or more vascular risk factors was 2.88 (95% CI, 1.46-5.69). No significant race × risk factor interactions were found. Late-life vascular risk factors were not associated with late-life brain amyloid deposition (for ≥2 late-life vascular risk factors vs 0: OR, 1.66; 95% CI, 0.75-3.69). CONCLUSIONS AND RELEVANCE: An increasing number of midlife vascular risk factors was significantly associated with elevated amyloid SUVR; this association was not significant for late-life risk factors. These findings are consistent with a role of vascular disease in the development of Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28399252      PMCID: PMC5921896          DOI: 10.1001/jama.2017.3090

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  38 in total

1.  Midlife pulse pressure and incidence of dementia: the Honolulu-Asia Aging Study.

Authors:  Michael H Freitag; Rita Peila; Kamal Masaki; Helen Petrovitch; G Webster Ross; Lon R White; Lenore J Launer
Journal:  Stroke       Date:  2005-12-08       Impact factor: 7.914

Review 2.  Cigarette smoking and dementia: potential selection bias in the elderly.

Authors:  Miguel A Hernán; Alvaro Alonso; Giancarlo Logroscino
Journal:  Epidemiology       Date:  2008-05       Impact factor: 4.822

3.  Brain arterial aging and its relationship to Alzheimer dementia.

Authors:  Jose Gutierrez; Lawrence Honig; Mitchell S V Elkind; Jay P Mohr; James Goldman; Andrew J Dwork; Susan Morgello; Randolph S Marshall
Journal:  Neurology       Date:  2016-03-16       Impact factor: 9.910

4.  Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.

Authors:  Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky
Journal:  J Nucl Med       Date:  2012-02-13       Impact factor: 10.057

5.  Stroke risk interacts with Alzheimer's disease biomarkers on brain aging outcomes.

Authors:  Timothy J Hohman; Lauren R Samuels; Dandan Liu; Katherine A Gifford; Shubhabrata Mukherjee; Elleena M Benson; Ty Abel; Frederick L Ruberg; Angela L Jefferson
Journal:  Neurobiol Aging       Date:  2015-06-06       Impact factor: 4.673

6.  Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia.

Authors:  Renaud La Joie; Audrey Perrotin; Louisa Barré; Caroline Hommet; Florence Mézenge; Méziane Ibazizene; Vincent Camus; Ahmed Abbas; Brigitte Landeau; Denis Guilloteau; Vincent de La Sayette; Francis Eustache; Béatrice Desgranges; Gaël Chételat
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

7.  Trends in prevalence and control of diabetes in the United States, 1988-1994 and 1999-2010.

Authors:  Elizabeth Selvin; Christina M Parrinello; David B Sacks; Josef Coresh
Journal:  Ann Intern Med       Date:  2014-04-15       Impact factor: 25.391

8.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

9.  Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly.

Authors:  Prashanthi Vemuri; Timothy G Lesnick; Scott A Przybelski; David S Knopman; Greg M Preboske; Kejal Kantarci; Mekala R Raman; Mary M Machulda; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Walter A Rocca; Rosebud O Roberts; Ronald C Petersen; Clifford R Jack
Journal:  Brain       Date:  2015-01-15       Impact factor: 13.501

Review 10.  Impaired Aβ clearance: a potential link between atherosclerosis and Alzheimer's disease.

Authors:  Ajay Gupta; Costantino Iadecola
Journal:  Front Aging Neurosci       Date:  2015-06-16       Impact factor: 5.750

View more
  186 in total

1.  Association of Head Injury with Brain Amyloid Deposition: The ARIC-PET Study.

Authors:  Andrea L C Schneider; Elizabeth Selvin; Menglu Liang; Lawrence Latour; L Christine Turtzo; Silvia Koton; Josef Coresh; Thomas Mosley; Christopher T Whitlow; Yun Zhou; Dean F Wong; Geoffrey Ling; Rebecca F Gottesman
Journal:  J Neurotrauma       Date:  2019-05-23       Impact factor: 5.269

2.  Temporal Sequence of Hearing Impairment and Cognition in the Baltimore Longitudinal Study of Aging.

Authors:  Nicole M Armstrong; Yang An; Luigi Ferrucci; Jennifer A Deal; Frank R Lin; Susan M Resnick
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-02-14       Impact factor: 6.053

3.  The Association of Late-Life Diabetes Status and Hyperglycemia With Incident Mild Cognitive Impairment and Dementia: The ARIC Study.

Authors:  Andreea M Rawlings; A Richey Sharrett; Marilyn S Albert; Josef Coresh; B Gwen Windham; Melinda C Power; David S Knopman; Keenan Walker; Sheila Burgard; Thomas H Mosley; Rebecca F Gottesman; Elizabeth Selvin
Journal:  Diabetes Care       Date:  2019-05-21       Impact factor: 19.112

Review 4.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

5.  The Association of Mid- and Late-Life Systemic Inflammation with Brain Amyloid Deposition: The ARIC-PET Study.

Authors:  Keenan A Walker; B Gwen Windham; Charles H Brown; David S Knopman; Clifford R Jack; Thomas H Mosley; Elizabeth Selvin; Dean F Wong; Timothy M Hughes; Yun Zhou; Alden L Gross; Rebecca F Gottesman
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

6.  Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study.

Authors:  Jennifer S Rabin; Aaron P Schultz; Trey Hedden; Anand Viswanathan; Gad A Marshall; Emily Kilpatrick; Hannah Klein; Rachel F Buckley; Hyun-Sik Yang; Michael Properzi; Vaishnavi Rao; Dylan R Kirn; Kathryn V Papp; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Jasmeer P Chhatwal
Journal:  JAMA Neurol       Date:  2018-09-01       Impact factor: 18.302

7.  Association Between Midlife Risk Factors and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities Study.

Authors:  Emily L Johnson; Gregory L Krauss; Alexandra K Lee; Andrea L C Schneider; Jennifer L Dearborn; Anna M Kucharska-Newton; Juebin Huang; Alvaro Alonso; Rebecca F Gottesman
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

8.  Neighborhoods, sleep quality, and cognitive decline: Does where you live and how well you sleep matter?

Authors:  Jaimie C Hunter; Elizabeth P Handing; Ramon Casanova; Maragatha Kuchibhatla; Michael W Lutz; Santiago Saldana; Brenda L Plassman; Kathleen M Hayden
Journal:  Alzheimers Dement       Date:  2018-02-01       Impact factor: 21.566

9.  Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease.

Authors:  Isabelle Bos; Stephanie J B Vos; Suzanne E Schindler; Jason Hassenstab; Chengjie Xiong; Elizabeth Grant; Frans Verhey; John C Morris; Pieter Jelle Visser; Anne M Fagan
Journal:  Alzheimers Dement       Date:  2019-08-01       Impact factor: 21.566

10.  Does Gender Influence the Relationship Between High Blood Pressure and Dementia? Highlighting Areas for Further Investigation.

Authors:  Anna E Blanken; Daniel A Nation
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.